While monotherapy with anti-PD-L1 or anti-LAG-3 showed only marginal efficacies, the combined therapy of JX to anti-PD-L1 or anti-LAG-3 revealed stronger anti-tumor efficacies and further suppressed the formation of malignant ascites within the peritoneal cavity compared with monotherapies. The gene discussed is LAG3; the disease is cancer.